Capricor Therapeutics, Inc. (CAPR)
CAPR Price and Sentiment
CAPR Latest news
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q3 2021 Results - Earnings Call Transcript
Capricor (CAPR) delivered earnings and revenue surprises of 22.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at the World Muscle Society Annual Meeting- -Met Primary Efficacy Endpoint of Mid Performance of Upper Limb (PUL) v1.2 (p=0.01)-
Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 92021-11-02 16:05
Company to Host Conference Call, November 9, 2021, at 4:30 p.m. ET Company to Host Conference Call, November 9, 2021, at 4:30 p.m. ET
Capricor Therapeutics Inc (NASDAQ: CAPR) has announced final data from Phase 2 HOPE-2 trial of CAP-1002 for advanced stages of Duchenne muscular dystrophy (DMD). The trial met its primary efficacy endpoint of mid-level performance of upper limb (mid-PUL v1.2) and various skeletal and cardiac function endpoints.
The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) increased by over 17% pre-market. This is why it happened.
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-10022021-09-24 07:00
–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–
- Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 -
Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?
-Conference Dates: September 13–15, 2021- -Conference Dates: September 13–15, 2021-